Top Markets
#1 GEKKO GEKKO +43.17%
#2 TENDIES TENDIES +39.20%
#3 ADO Protocol ADO Protocol +38.64%
#4 Pons Pons +36.87%
#5 Helium Helium +27.97%
#6 Prom Prom +25.93%
#7 龙虾 (Lobster) 龙虾 (Lobster) +20.86%
#8 Nillion Nillion +18.38%
#9 o1.exchange o1.exchange +17.72%
#10 Main Street Yield Main Street Yield +17.48%
Coin of the day
GEKKO GEKKO
Settings
Language
ENGLISH
Currency
USD
Theme
Gubra A/S Gubra A/S

Gubra A/S

GUBRA
Rank in Stocks #9438
Gubra A/S is a biotechnology firm engaged in two core activities: offering... Gubra A/S is a biotechnology firm engaged in two core activities: offering contract research organization (CRO) services for pre-clinical development, and advancing its own internal early-stage drug and target discovery initiatives. Its CRO division provides specialized pre-clinical research and development support to companies in the pharmaceutical and biotechnology sectors. These services encompass a wide range of capabilities, including in vivo pharmacology, tissue analysis, various assay development, molecular pharmacology, bioanalytical testing, next-generation sequencing (NGS), and both two-dimensional and three-dimensional imaging techniques. Established in 2008, the company has its headquarters in Horsholm, Denmark.
Share Price
$61.73
Last synced: 2026-08-28
Market Cap
$1.01B
Change (1 day)
-1.02%
Change (1 year)
5.10%
Country
DK
Trade Gubra A/S (GUBRA)

Category

Healthcare
P/E ratio for Gubra A/S (GUBRA)
P/E ratio as of 2026 TTM: 0
According to Gubra A/S latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Gubra A/S from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.